sciencemag.org
46%
419
AstraZeneca reports powerful COVID-19 protection in new vaccine trial
Kai Kupferschmidt, Gretchen VogelScience’s COVID-19 reporting is supported by the Heising-Simons Foundation.The long-awaited results from a new trial of AstraZeneca’s COVID-19 vaccine hold some good news for the company, which in recent weeks has had to address eroding confidence in its shots amid news of possible rare, serious side effects. In a press release published on Monday morning, the company announced that the trial, which included more than 32,000 participants in Chile, Peru, and the United States, had shown the vaccine to have 79% efficacy at preventing symptomatic COVID-19.“I’m thrilled,” says Ashish Jha, dean of Brown University’s School of Public Health.